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heart failure, and non-fatal stroke. RESULTS: The
ACE/CCB-combination showed a beneﬁcial effect on
HbA1c values, and the resulting event rate in this group
is lower than for patients treated with ﬁxed combinations
like atenolol/chlorthalidone or enalapril/hydrochloroth-
iazide. Extrapolating data from one study, the relative
risk was lowered by 20% for most diabetes-related events
in comparison to atenolol/chlorthalidone. “Cataract
extraction” and “renal failure” were reduced by 19%,
“blindness” by 30%. The risk reduction for CVD
amounted 13% for non-fatal myocardial infarction, 12%
for non-fatal stroke. In the second study, the relative 
risk for “Cataract extraction” is reduced by 16% in 
the ACE/CCB-group after 10 years, compared to the 
patient group treated with a combination enalapril/
hydrochlorothiazide. The risk reduction for CVD
amounted 17% for non-fatal myocardial infarction and
16% for non-fatal stroke. CONCLUSION: The use of
this computerized model allows gaining insight into the
long-term medical outcomes of the treatment with ACE/
CCB-combination in hypertensive type-2 diabetics. The
model shows a beneﬁcial effect for the combination 
trandolapril/verapamil in diabetic patients because of the
additional HbA1c decreasing effect beside the hyperten-
sion management.
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OBJECTIVE: The primary objective is to evaluate the
clinical and economic outcomes of monotherapy with a
sulfonylurea versus dual therapy with metformin and a
sulfonylurea in a county health care system. METHODS:
This is a retrospective, chart-review, study in which the
patients will serve as their own controls, prior to starting
dual therapy. All patients are evaluated two years prior
to and post the addition of the second agent, metformin.
Data collected will include the following: HbA1C, fasting
blood glucose, lipid proﬁle, and liver and renal function
tests, adverse drug reactions, number of hospital and
emergency room admissions, number and type of clinic
visits, and number of operations/procedures/and diag-
nostic tests. The t-test for paired data is utilized to analyze
the continuous variables. RESULTS: A total of 124
patients enrolled in this study, with a mean duration of
diabetes of 6.68 years (SD 4.62). The average HbA1c on
monotherapy is 10.5% versus 10.2% on dual therapy
(NS). The average fasting blood glucose is 229mg/dL 
on monotherapy versus 192mg/dL on dual therapy 
(p < 0.05). For the economic outcomes on monotherapy
there is an average of 1.31 visits per patient versus 1.43
visits on dual therapy to the emergency room, hospital,
and to ambulatory care clinics. On monotherapy, 31% of
the patients had procedures and 37% had diagnostic
tests, compared to 38% and 51% respectively, on dual
therapy. CONCLUSIONS: This study does point to better
clinical outcomes with dual therapy; however, there is a
concurrent rise in the resource utilization. This increase
could be due to more education on the physician side 
for preventive practices and to an increase in the patient
access within the system. More research, especially
prospectively designed studies, need to be conducted to
determine the exact clinical and economic impact of dual
oral therapy for diabetes.
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OBJECTIVE: Implementing an internet-based managed
care model for diabetes care in Switzerland. METHODS:
The CareCard Diabetes is a national standard for diabetes
care in Switzerland. In a joint approach the largest Swiss
health insurance and an urban general practitioners’ asso-
ciation have launched a joint quality assurance initiative
for diabetes care in Luzern. An Internet quality assurance
database is used to connect the physicians. Data from the
CareCard were supplemented with speciﬁc anamnestic
data and information regarding diabetes medication in
order to allow for cost-effectiveness and risk analyses.
The data are presented to the physician in several ways.
Most important is a weighted problem list as a feedback
to the GP, which gives advice on how to improve the dia-
betes care for each patient. The diabetic has access to the
online CareCard Diabetes and via web-interface or call-
center, and the entry of self-control data is possible. The
physician in return has access to the self-control data of
the patient and can derive information for the optimisa-
tion of the therapy. Quality campaigns help to facilitate
the use of the system and to promote widely accepted
guideline knowledge into routine diabetes care. A proof-
of-concept study in Luzern has started in June 2001, with
currently 176 patients being enrolled. RESULTS: HbA1c
values decreased in type 2 diabetes patients from 7.3%
to 6.9% (p < 0.05). Men initially had worse HbA1c levels
and showed greater improvements -0.5% than women
did -0.2% (p < 0.05). Results from an additional HbA1c
quality assurance campaign found a relevant deviation of
practice measured HbA1c levels (mean 6.9 % +/- 1.4%)
in comparison to reference laboratory measurements
(mean 7.3 % +/- 1.4%). The study will end in June 2003.
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CONCLUSION: The CareCard Diabetes was found to be
an up-to-date standard for implementing a quality of care
initiative in Switzerland. The internet offers possibilities
to extend the value of this originally paper-based tool for
improving quality of diabetes care.
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OBJECTIVES: Type-2 diabetes increases the risk of 
cardiovascular and cerebrovascular complications. In
general population, overweight/obesity are associated
with high risk of related diseases. In a type-2 diabetes
patient’s population, we examine the relationship
between BMI status and incidence of cardiovascular and
cerebrovascular complications. METHODS: We used a
cohort of type-2 diabetes patients over a 15-year period.
Study patients were stratiﬁed in 4 BMI groups: 20–
24.9kg/m2 (normal weight), 25–29.9kg/m2 (overweight),
30–34.9kg/m2 (obese) and over 35kg/m2 (very obese).
Incidence of diseases was analyzed retrospectively 
(p < 0.05) in each BMI group relative to the “normal
weight” group. RESULTS: Five thousand four hundred
and thirty ﬁve type-2 diabetes patients were examined.
Average age was 63.61 years and 44 % of the population
was women. Number of patients per group were 1,060
normal weight, 2,072 overweight, 1,454 obese and 849
very obese. Average follow-up (734 days) and average
duration of diabetes history (15 years) were comparable
in each BMI group relative to normal weight group. Inci-
dence of myocardial infarction are 1.13%, 4.05% 
(p < 0.05, Chi2), 2.48% (p < 0,05, Chi2) and 1.53% 
(p > 0.05, Chi2); incidence of coronarography are 0.57%,
1.40% (p < 0.05, Chi2), 1.65% (p < 0.05, Chi2) and
1.77% (p < 0.05, Chi2), respectively in normal weight,
overweight, obese and very obese. PTCA and CABG are
more frequent in obese group compare to normal weight.
HbA1c is normalized (below 7%) in higher proportion of
normal weight patients (21.89%) compare to obese
(18.50%, p < 0.05, Chi2). Incidence of cerebrovascular
events such as stroke or TIA are not statistically different
according to BMI group. CONCLUSION: In this analy-
sis, variables like follow-up and duration of diabetes
history were homogeneously distributed among BMI
groups. In this cohort of type-2 diabetes patients, we
observed that cardiovascular events are more frequent in
overweight/ obese compared to normal weight. Further
research will need to conﬁrm that a relevant weight reduc-
tion would have a clinical beneﬁt in this high-risk patients
population.
DIABETES—Quality of Life/Preference
PDB9
DEVELOPMENT AND VALIDATION OF THE
INSULIN TREATMENT SATISFACTION
QUESTIONNAIRE (ITSQ)
Anderson RT1, Skovlund SE2, Marrero D3, Brod M4, ITSQ
Study Group5
1Wake Forest University School of Medicine, Winston-Salem,
NC, USA; 2Novo Nordisk, Sorgenfri, Denmark; 3Indiana
University, Indianapolis, IN, USA; 4The Brod Group, Mill Valley,
CA, USA; 5 ITSQ, US, UK, Japan, Denmark, USA
OBJECTIVES: Patient reported Treatment Satisfaction
instruments can be used to assess degree of acceptability
and effectiveness of a treatment. For diabetes, this assess-
ment can be helpful for guiding treatment decisions about
the most optimal insulin therapy regimens for a given
patient. Unfortunately, there are no instruments identi-
ﬁed in the literature that assess the full spectrum of 
satisfaction issues with insulin therapies. Therefore, we 
undertook the development and validation of the com-
prehensive Insulin Treatment Satisfaction Questionnaire
(ITSQ). METHOD: An original item pool was developed
using data collected from ﬁve focus groups with insulin
users, current literature and consultation with behavioral
diabetes researchers. The initial questionnaire was tested
in 170 diabetes patients from 3 large clinical centers in
different regions of the US who were currently using a
variety of insulin regimens. A conﬁrmatory psychometric
study in 402 insulin users was subsequently conducted.
RESULTS: Item and scale analysis with IRT and factor
analysis resulted in the identiﬁcation of six subscales:
Ease/Convenience, Interference, Lifestyle, Hypoglycemia,
Glycemic control, and Insulin Delivery System. Cronbach
alpha reliability ranged from .79 to .92, and 2-week test-
retest reliability (n = 35) ranged from 0.65 to 0.89. Con-
vergent validity of the ITSQ was established in relation
to several questionnaires, including the PAID, insulin self-
efﬁcacy and diabetes symptoms questionnaires. The ITSQ
subscales discriminated signiﬁcantly for A1c level, Type 1
vs. Type 2 diabetes, and global satisfaction. The conﬁr-
matory validation study conﬁrmed the original six-factor
structure and the discriminative validity. The ﬁnal short-
ened ITSQ contains 25 items, which may be reported as
a total score or as 6 subscale scores. CONCLUSION: The
ITSQ is a comprehensive and psychometrically valid
instrument covering six distinct dimensions of treatment
satisfaction with insulin. It is applicable to type-1 and 2
diabetes patients and a wide range of insulin regimens.
